title: Counseling patients about sexual issues.
abstract: In recent years, the frequency of antidepressant drug-induced sexual dysfunction has increased, along with the use of new drugs for the treatment of erectile dysfunction and premature ejaculation. It has thus become common for pharmacists to counsel patients about sexual issues. Pharmacists must not only become knowledgeable about these drugs and their indications, but they must also become skilled and comfortable with counseling patients and answering questions from both patients and other health care providers. In addition to therapeutic information, pharmacists' discussions with patients should take into account factors that contribute to treatment nonadherence and treatment failure. Patient education is essential to ensure optimum outcomes for pharmacologic treatments for both erectile dysfunction and premature ejaculation. Improper use of phosphodiesterase-5 inhibitor drugs for erectile dysfunction accounts for most nonresponsiveness and discontinuation of treatment. Drug-induced sexual dysfunction is common with some psychotropic drugs. Up to 50% of men will experience delayed ejaculation, and at least 30% of men and women will experience anorgasmia from antidepressant drugs with serotonin agonist activity. Trazodone is the drug most commonly associated with the rare but very serious adverse effect of priapism. The pharmacist who is both competent and comfortable discussing sexual function and dysfunction with patients can make positive contributions to their therapeutic outcomes as well as their quality of life.
authors.affiliation: School of Pharmacy, University of Southern California, Los Angeles, California 90089-9121, USA.
authors.forename: Glen L
authors.initials: GL
authors.lastname: Stimmel
authors.forename: Mary A
authors.initials: MA
authors.lastname: Gutierrez
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000928:Antidepressive Agents / Q000009:adverse effects; D003376:Counseling; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D010353:Patient Education as Topic; D011317:Priapism / Q000139:chemically induced / Q000523:psychology; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced / Q000523:psychology*; D014196:Trazodone / Q000009:adverse effects
chemical_list: D000928:Antidepressive Agents; D004791:Enzyme Inhibitors; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human; D014196:Trazodone